Mechanism study of simvastatin combined with ezetimibe in treatment of coronary heart disease
10.13699/j.cnki.1001-6821.2015.19.003
- VernacularTitle:辛伐他汀联合依折麦布对冠心病患者的作用机制研究
- Author:
Shan HUANG
1
;
Tian-Fa LI
;
Wei-Jing LI
;
Yue-Qiong KONG
;
Yun LIN
Author Information
1. 海南医学院附属医院心内科
- Keywords:
coronary heart disease;
simvastatin;
ezetimibe;
microRNA155;
tumor necrosis factor-α;
C reaction pro-tein
- From:
The Chinese Journal of Clinical Pharmacology
2015;31(19):1901-1903
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the impact of simvastatin and ezetimibe on the changes of plasma microRNA 155 and TNF -α, C-reactive protein level of patients with coronary heart disease . Methods Ninety -five patients were randomly divided into treatment group(n=49) and control group (n=46).Patients in two groups were given conventional treatment . Patients in treatment group were given simvastatin 20 mg, and ezetimibe 10 mg, qn, patients in control group only given ezetimibe .Two groups were treated for 12 weeks.The levels of plasma microRNA155 and serum tumor necrosis factor -α( TNF-α) , C reactive protein , low density lipoprotein cholesterol ( LDL -C ) and cholesterol ( TC ) before and after treatment were compared between two groups. Result The levels of microRNA155 , TNF -α, C reactive protein after treatment of the two groups were significantly lower than those before treatment ( P<0.05 ) , and treatment group were lower than control group ( P<0.05 ) .The LDL -C and TC after treatment of the two groups were significantly lower than before treatment ( P <0.05 ) , and treatment group were significantly lower than control group (P<0.05).No obvious adverse reaction was observed in two groups. Conclusion The mechanism of simvastatin and ezetimibe in treatment of coronary heart disease may be related to the decreased levels of plasma microRNA 155 and serum TNF-αand C reac-tive protein.
